TB-500 / TB4
peptideevidence: emerging · v1.0.0Description
TB-500 (thymosin beta-4 fragment) is a 17-amino-acid synthetic peptide derived from the active region of thymosin beta-4. Studied in cellular-repair and angiogenesis research models. Lyophilized powder. Reconstitute with bacteriostatic water for in-vitro research. Store at -20°C. Certificate of Analysis attached to this listing.
Mechanism summary
Actin regulation; potential cell migration and repair signaling.
How it works
TB-500, a synthetic 7-amino-acid fragment of thymosin beta-4, functions primarily through its actin-binding properties, which are crucial for cellular processes such as migration, proliferation, and differentiation. The peptide retains the actin-binding region of the full-length thymosin beta-4, allowing it to influence cellular dynamics and tissue repair mechanisms. While most human research has focused on the full-length thymosin beta-4, the TB-500 fragment is believed to promote healing and recovery in various tissues by enhancing cellular movement and reducing inflammation.
In preclinical studies, TB-500 has demonstrated the ability to improve collagen organization and fibril diameter in tendon repair models, as noted by Kim & Bhatt (2013). Additionally, Bock-Marquette et al. (2004) showed that thymosin beta-4 reduces infarct volume and preserves cardiac function in mouse models of myocardial infarction. However, it is important to note that there is no published human randomized controlled trial (RCT) specifically for the TB-500 fragment, and most evidence is extrapolated from studies on the full-length peptide.
The mechanism of action includes modulation of inflammatory signaling pathways, which may contribute to its potential therapeutic effects in wound healing and tissue regeneration. However, the long-term effects of TB-500 on immune modulation and angiogenesis remain theoretical and have not been thoroughly studied in humans. The absence of direct human safety data for the TB-500 fragment necessitates caution in its use, particularly in populations with specific health concerns. [Source: Peptide Dosing Protocols]
In plain language
TB-500 helps with healing by influencing cell movement and reducing inflammation, but most evidence comes from studies on a longer version of the peptide.
Reference details
Route(s)
subcutaneous
Tags
repair
Active
yes
Product details · BT10
Price
$69.99
Stock
out of stock
Purity
≥ 99%
Amino sequence: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Thymosin β-4 active fragment)
COA: View certificate (batch TET-4906-A) →
Teton Labs product catalog · research-use compound data.
💉 Dosing — 3 references (verbatim from source · not a recommendation)
Dose
2-2.5 mg SC twice weekly (loading 4-6 weeks), then 2 mg weekly maintenance
Route
subcutaneous
Frequency
twice weekly (loading), then weekly
Duration
4-6 week loading, then maintenance
Cycle
Loading phase then maintenance phase
Reconstitution
Reconstitute with bacteriostatic water
Vial
Commonly 5 mg or 10 mg vials
Source: Practitioner Peptide Dosing Reference (commonly published ranges) — Compiled practitioner reference (internal_protocol)Source-backedProvider-reviewed
Dose
2-2.5 mg per injection (loading); 750 mcg-2 mg (maintenance)
Route
subcutaneous or oral or topical
Reconstitution
Bacteriostatic water
Source: Peptide Protocol Wiki (peptideprotocolwiki.com) (publication)Source-backedProvider-reviewed
Dose
Standard: 2-2.5 mg subcutaneous twice weekly · Low: 2 mg twice weekly · High: 2.5 mg subcutaneous once weekly
Route
subcutaneous injection
Frequency
twice weekly for loading, once weekly for maintenance
Duration
Weeks 1-6 for loading, Weeks 7-12 for maintenance
Cycle
4-12 weeks
Reconstitution
2.0 mL bacteriostatic water for 10 mg vial
Source: Peptide Dosing Protocols (peptidedosingprotocols.com) (publication)Source-backedProvider-reviewed
Safety, contraindications & monitoring
Contraindications — who should avoid
- Not FDA-approved for human use.
- Should be avoided by individuals on the World Anti-Doping Agency Prohibited List.
Safety & side effects
- No dose-limiting toxicities reported in a Phase 1 study of full-length thymosin beta-4.
Monitoring & bloodwork
- CBC at baseline and week 4
Clinical evidence
- The strongest human evidence is still for full-length thymosin beta-4 in topical or ophthalmic formulations, not injectable TB-500.
Source-backedProvider-reviewedApproved findings drawn from your sources — decision support, not medical advice.
Provider-only reference. This page does not constitute medical advice, a recommendation, or dosing guidance.